Literature DB >> 18062799

Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type.

C Schoenbein1, W-D Docke, K Wolk, G Belbe, C Hoflich, M Jung, G Grutz, W Sterry, H-D Volk, K Asadullah, R Sabat.   

Abstract

Interleukin (IL)-10 is one of the most crucial immunoregulatory cytokines. Its short-term effects have been analysed extensively, but little is known about its long-term effects. This is of considerable importance, as high systemic IL-10 levels are present for long periods in patients with persistent viral infections, certain cancers and in critical care patients. Our study investigated the effects of the long-term presence of IL-10 on human peripheral blood monocytes. In vitro, IL-10 treatment of these cells for 7 days induced the development of a novel cell type characterized by unique phenotypical and functional characteristics. These cells showed high HLA-DR expression and low expression of CD86 and other co-stimulatory molecules on their surface. The mRNA levels of both HLA-DR and CD86 were high, but no intracellular accumulation of CD86 protein was observed. With respect to its function, these cells showed strongly diminished tumour necrosis factor-alpha production following lipopolysaccharide stimulation, strongly diminished allogenic CD4(+) T cell stimulatory capacity, and even induced a hyporesponsive state in CD4(+) T cells. The phenotype remained stable despite the removal of IL-10. In vivo, we found monocytic cells from patients exhibiting this phenotype after long-term IL-10 exposure. These results complement our knowledge further about the biological effects of IL-10 and may provide an explanation for the sustained immunodeficiency in cases of the persistent presence of systemic IL-10.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18062799      PMCID: PMC2276947          DOI: 10.1111/j.1365-2249.2007.03554.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia.

Authors:  Steven G Muehlstedt; Mark Lyte; Jorge L Rodriguez
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

2.  CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages.

Authors:  Tatsushi Katakura; Masaru Miyazaki; Makiko Kobayashi; David N Herndon; Fujio Suzuki
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

3.  Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock.

Authors:  Y Heper; E H Akalin; R Mistik; S Akgöz; O Töre; G Göral; B Oral; F Budak; S Helvaci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

4.  Impaired antigen presentation by human monocytes during endotoxin tolerance.

Authors:  K Wolk; W D Döcke; V von Baehr; H D Volk; R Sabat
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

5.  Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

Authors:  K Asadullah; M Friedrich; S Hanneken; C Rohrbach; H Audring; A Vergopoulos; M Ebeling; W D Döcke; H D Volk; W Sterry
Journal:  J Invest Dermatol       Date:  2001-05       Impact factor: 8.551

6.  Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha.

Authors:  Sergio Rutella; Giuseppina Bonanno; Luca Pierelli; Andrea Mariotti; Ettore Capoluongo; Anna Maria Contemi; Franco Ameglio; Antonio Curti; Daniela G De Ritis; Maria Teresa Voso; Alessandro Perillo; Salvatore Mancuso; Giovanni Scambia; Roberto M Lemoli; Giuseppe Leone
Journal:  Eur J Immunol       Date:  2004-05       Impact factor: 5.532

7.  IL-10 inhibits cytokine production by activated macrophages.

Authors:  D F Fiorentino; A Zlotnik; T R Mosmann; M Howard; A O'Garra
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

8.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

9.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  2 in total

1.  Characterisation of interleukin-10 expression on different vascular structures in allergic nasal mucosa.

Authors:  Barbara Muller; Danielle van Egmond; Esther Jj de Groot; Wytske J Fokkens; Cornelis M van Drunen
Journal:  Clin Transl Allergy       Date:  2014-01-10       Impact factor: 5.871

2.  The therapeutic effects of traditional Chinese medicine Fusu agent in LPS-induced acute lung injury model rats.

Authors:  Peiyang Gao; Ziyi Zhao; Chuantao Zhang; Chunxia Wang; Kunlan Long; Liuxue Guo; Baixue Li
Journal:  Drug Des Devel Ther       Date:  2018-11-13       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.